Massachusetts' Inotek Exploring Strategic Alternatives After Another Glaucoma Trial Failure Post author:Sam Post published:July 9, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Acorda Plunges After the FDA Rejects Marketing App for Parkinson's Disease Drug August 28, 2017 This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017 TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO June 4, 2017
This Boston Biotech Gets $57.5 Million Upfront, $2.1 Billion Commitment From Drug Giant AstraZeneca PLC May 2, 2017
TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO June 4, 2017